TY - JOUR
T1 - ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis
AU - Lemaître, Vincent
AU - O'Byrne, Timothy K.
AU - Borczuk, Alain C.
AU - Okada, Yasunori
AU - Tall, Alan R.
AU - D'Armiento, Jeanine
PY - 2001
Y1 - 2001
N2 - Matrix metalloproteinase- (MMP-1), or interstitial collagenase, has been hypothesized to contribute to the progression of the human atherosclerotic lesions by digesting the fibrillar collagens of the neointimal ECM. The apoE knockout (apoE0) mouse model develops complex atherosclerotic lesions, but mice do not possess a homologue for MMP-1. To provide an in vivo evaluation of the role of MMP-1 in atherogenesis, we created a transgenic mouse model that expresses this enzyme specifically in the macrophage, under the control of the scavenger receptor A (SCAV) enhancer/promoter. The MMP-1 transgenic mice were crossed into the apoE0 background and fed an atherogenic diet for 16-25 weeks. Surprisingly, the transgenic mice demonstrated decreased lesion size compared with control littermates. The lesions of the transgenic animals were less extensive and immature, with fewer cellular layers and a diminished content of fibrillar collagen. There was no evidence of plaque rupture. Our data suggest that remodeling of the neointimal ECM by MMP-1 is beneficial in the progression of lesions.
AB - Matrix metalloproteinase- (MMP-1), or interstitial collagenase, has been hypothesized to contribute to the progression of the human atherosclerotic lesions by digesting the fibrillar collagens of the neointimal ECM. The apoE knockout (apoE0) mouse model develops complex atherosclerotic lesions, but mice do not possess a homologue for MMP-1. To provide an in vivo evaluation of the role of MMP-1 in atherogenesis, we created a transgenic mouse model that expresses this enzyme specifically in the macrophage, under the control of the scavenger receptor A (SCAV) enhancer/promoter. The MMP-1 transgenic mice were crossed into the apoE0 background and fed an atherogenic diet for 16-25 weeks. Surprisingly, the transgenic mice demonstrated decreased lesion size compared with control littermates. The lesions of the transgenic animals were less extensive and immature, with fewer cellular layers and a diminished content of fibrillar collagen. There was no evidence of plaque rupture. Our data suggest that remodeling of the neointimal ECM by MMP-1 is beneficial in the progression of lesions.
UR - http://www.scopus.com/inward/record.url?scp=0035019911&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035019911&partnerID=8YFLogxK
U2 - 10.1172/JCI9626
DO - 10.1172/JCI9626
M3 - Article
C2 - 11375412
AN - SCOPUS:0035019911
SN - 0021-9738
VL - 107
SP - 1227
EP - 1234
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 10
ER -